Not for release to US wire services or distribution in the United States Alterity Therapeutics Announces that the Securities Purchase Plan (SPP) Documents have been Dispatched to Eligible Shareholders MELBOURNE, AUSTRALI

Not for release to US wire services

or distribution in the United States

Alterity Therapeutics Announces

that the Securities Purchase Plan (SPP)

Documents have been Dispatched to Eligible Shareholders

MELBOURNE, AUSTRALIA AND SAN FRANCISCO,

USA - 10 January 2024: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"),

a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that the

offer documents for the Securities Purchase Plan (SPP) approved by shareholders at the Extraordinary General Meeting on 29 December 2023

have been dispatched to eligible shareholders today.

Eligible shareholders with a registered

address in Australia and New Zealand at the record date (7.00 pm on 21 November 2023) are invited to participate in an SPP under which

shares and free- attaching options will be offered on the same terms as the Placement announced on 22 November 2023 up to a maximum of

A$30,000 per eligible shareholder. The maximum total subscription under the SPP is A$2 million. The SPP offer is only being made to shareholders

with a registered address in Australia or New Zealand in the register of members of the Company, having regard to the compliance costs

of making the SPP offer in other jurisdictions.

Key Dates for the SPP

Note: The timetable above is indicative

only and subject to variation. The Company reserves the right to alter the timetable as its absolute discretion and without notice, subject

to the ASX Listing Rules and Corporations Act 2001 (Cth).

The proceeds from this

financing will provide ongoing funding of Alterity's Phase 2 clinical trials in Multiple System Atrophy (MSA), planning for a

potential Phase 3 clinical trial in MSA, continuing discovery and research efforts in neurodegenerative diseases, including

Parkinson's Disease, and general working capital.

About Alterity Therapeutics Limited

Alterity Therapeutics is a clinical

stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company's

lead asset, ATH434, has the potential to treat various Parkinsonian disorders and is currently being evaluated in two Phase 2 clinical

trials in Multiple System Atrophy. Alterity also has a broad drug discovery platform generating patentable chemical compounds to treat

the underlying pathology of neurological diseases. The Company is based in Melbourne, Australia, and San Francisco, California, USA. For

further information please visit the Company's web site at www.alteritytherapeutics.com.

Authorisation & Additional information

This announcement was authorized by David Stamler, CEO of Alterity

Therapeutics Limited.

Investor and Media Contacts:

Forward Looking Statements

This press release contains

"forward-looking statements" within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities

Exchange Act of 1934. The Company has tried to identify such forward-looking statements by use of such words as "expects," "intends,"

"hopes," "anticipates," "believes," "could," "may," "evidences" and "estimates,"

and other similar expressions, but these words are not the exclusive means of identifying such statements.

factors that could cause actual results to differ materially from those indicated by such forward-looking statements are described

in the sections titled "Risk Factors" in the Company's filings with the SEC, including its most recent Annual

Report on Form 20-F as well as reports on Form 6-K, including, but not limited to the following: statements relating to the

Company's drug development program, including, but not limited to the initiation, progress and outcomes of clinical trials of the

Company's drug development program, including, but not limited to, ATH434, and any other statements that are not historical facts.

Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to the

difficulties or delays in financing, development, testing, regulatory approval, production and marketing of the Company's drug

components, including, but not limited to, ATH434, the ability of the Company to procure additional future sources of financing,

unexpected adverse side effects or inadequate therapeutic efficacy of the Company's drug compounds, including, but not limited to,

ATH434, that could slow or prevent products coming to market, the uncertainty of obtaining patent protection for the Company's

intellectual property or trade secrets, the uncertainty of successfully enforcing the Company's patent rights and the

uncertainty of the Company freedom to operate.

Any forward-looking statement

made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is

made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time

to time, whether as a result of new information, future developments or otherwise.